7 days ago
SF Healthcare Week: Affinity Asset Advisors' Head of Research Patrick Nosker shares his take on Monday's conference news, and discusses some of his fund's top holdings
He talks about todays M&A heavy news and the market reaction to it, and comments on Xenon, Madrigal, Nurix, and Wave.
7 days ago
SF Healthcare Week: Flagship Pioneering's Noubar Afeyan on Moderna, gov't policy, China, and "polyintelligence" in drug development
He shares his thoughts on Moderna's transition, what policies he would like to see promoted in government, competing with China, and the...
7 days ago
SF Healthcare Week: Baird's Brian Skorney shares his take on this morning's conference news, the year ahead, and his top picks
He discusses news from Biogen and Regeneron, and shares his top picks Xenon, Soleno, and Lexeo.
Jan 10
Jon Norris shares highlights from the 2024 HSBC Venture Healthcare Full-Year Report
He provides a 2024 year-end recap and 2025 outlook DOWNLOAD THE FULL REPORT #Sponsored
Dec 18, 2024
Baird biotech analyst Jack Allen recaps ASH and other recent news, and shares his outlook for top names in 2025
Jack Allen discusses data that Arcellx and Vor had at last week's ASH annual meeting, and discusses Mereo, Ultragenyx, Instil Bio, Taysha...
Dec 16, 2024
Dimension's Zavain Dar talks about raising a $500M second fund, and describes the firm's ethos of investing in companies that are highly focused in both life sciences and technology
He discusses the founding of Dimension, and highlights entrepreneurs and portfolio companies that have matched the firm's focused...
Dec 10, 2024
NewYorkBIO CEO Jennifer Hawks Bland discusses their annual event at the New York Stock Exchange and what is on the mind of companies today
Over 600 people registered for the event and took in company presentations and networking on the floor of the NYSE.
Dec 7, 2024
ApexOnco's Jacob Plieth shares his take on what to watch for at the 2024 ASH Annual Meeting
He talks modalities and targets, and comments on Arcellx, Galapagos, BeiGene, Nurix, Kura, JNJ, Syndax, AbbVie AstraZeneca, CellCentric,...
Nov 20, 2024
London Healthcare Week: Forbion Managing Partner Sander Slootweg shares his thoughts on the year ahead, the IPO market, M&A environment, areas of interest, and more
Fresh off of raising more than €2 billion for two new funds in October, he gives his take on the biotech markets both in Europe and...
Nov 20, 2024
From Seoul: Kicking off BiotechTV's one week visit to Korea by getting an overview of the growth and current state of biotech in the country from KoreaBIO
KoreaBIO Vice President Seung-Kyou Lee and Director of International & Public Affairs Jurie Hwang describe the enormous growth the sector...
Nov 9, 2024
SITC 2024: Parker Institute for Cancer Immunotherapy CSO John Connolly gives an overview of the latest advances in IO
He discusses the latest in TILs, cell therapy, multispecifics, oncolytic viruses and more.
Nov 7, 2024
BioHouston CEO Ann Tanabe kicks off the 2024 Texas Life Science Forum
From the largest conference for life sciences in Texas each year, she describes the significant growth in infrastructure, startups,...
Nov 5, 2024
BIO-Europe: Pareto Securities' Biotech Analyst Dan Akschuti shares his thoughts on the conference and discusses recent company successes in the nordic region
He says there has been an upswing in investors looking at companies. Plus, his thoughts on BioInvent, Oculis, and Camurus. Brought to you by
Nov 5, 2024
BIO-Europe: Karolinska Institutet professor and physician Anna Wedell discusses the work she is doing and what areas of research excite her today
She discusses building systems around early diagnostics and treatment, rare disease discovery, mitochondrial disease and the brain,...
Nov 4, 2024
BIO-Europe: The CEO of Flerie, a publicly traded life sciences investment firm, discuses the firm's investment strategy and the health of biotech in the region
Ted Fjällman covers the history of the firm, and rationale for going public this year. Plus, he highlights portfolio companies such as...
.png){kind=logo}
